Journal of Chemotherapy最新文献

{"title":"Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR.","authors":"Marko Skelin, Kaja Matić, Andrea Anić-Matić, Ivan Krečak, Bruna Perkov-Stipičin, Mirko Grubor","doi":"10.1080/1120009X.2025.2492935","DOIUrl":"10.1080/1120009X.2025.2492935","url":null,"abstract":"<p><p>Mesothelioma has a poor prognosis, with a 5-year overall survival (OS) rate less than 5%. Immunotherapy has been proven as a promising alternative to platinum-based therapies in first-line treatment. Our systematic literature search included 7 randomized clinical trials involving 2,549 patients to evaluate the impact of immunotherapy on OS across different lines of therapy, histologic subtypes, and ECOG performance status, and to assess the correlation between OS, progression-free survival (PFS), and objective response rate (ORR). Immunotherapy significantly improved OS (HR 0.78, <i>P</i> = 0.0005) with a similar benefit observed in first-line and second/later-line treatment (<i>P</i> = 0.25) as well as in all ECOG statuses (<i>P</i> = 0.32). A significantly greater benefit was observed in non-epithelioid compared to epithelioid mesothelioma (<i>P</i> = 0.002). Additionally, a strong correlation was shown only between OS and PFS (<i>r</i> = 0.86, <i>P</i> = 0.01). Our results emphasize the importance of immunotherapy in mesothelioma and further support PFS as a surrogate endpoint.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"290-301"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a retrospective study.","authors":"Li Huang, Hui Rao, Chunmei Wu, Xiaohui Liu, Yipeng Song, Gangfeng Zhu, Miao He","doi":"10.1080/1120009X.2025.2532912","DOIUrl":"10.1080/1120009X.2025.2532912","url":null,"abstract":"<p><p>This study explored the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced proficient mismatch repair/microsatellite stable-type colorectal cancer. We retrospectively collected data from patients (n=75) diagnosed with advanced colorectal cancer at our hospital from January 2020 to December 2022 who chose to receive fruquintinib monotherapy or combine it with immune checkpoint inhibitors for treatment. The primary endpoint was progression-free survival (PFS) and overall survival (OS). As of July 1, 2023, the median PFS for the fruquintinib monotherapy group and combination therapy was 3.9 months and 7.9 months , respectively (P = 0.142). The median OS in the monotherapy group and combination therapy was 10.3 months and 10.0 months, respectively (P = 0.942). However, as compared with the monotherapy group, the combination therapy group showed a trend for a prolonged duration of PFS, and it may have good application potential.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"217-224"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single versus two doses of palonosetron for prevention of chemotherapy-induced nausea and vomiting in children: a double-blind placebo controlled randomized study.","authors":"Sandeep Jain, Neeraj Teotia, Payal Malhotra, Gauri Kapoor","doi":"10.1080/1120009X.2025.2488598","DOIUrl":"10.1080/1120009X.2025.2488598","url":null,"abstract":"<p><p>This single-centre, double-blinded, placebo-controlled randomized study aimed to assess the efficacy of single versus two doses of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Children receiving multiple-day (scheduled for ≥3 days) moderately or highly emetogenic chemotherapy (MEC/HEC) were randomized to receive either a single (day 1) or two doses (days 1 and 4) of intravenous palonosetron, in addition to the standard antiemetic prophylaxis. The primary efficacy endpoint was the proportion of patients with complete response (CR) for CIV in acute phase. One-hundred children receiving 307 blocks of MEC/HEC were randomized to receive one (Group A; <i>n</i> = 51) or two doses (Group B; <i>n</i> = 49) of palonosetron. Proportion of children showing CR for CIV was significantly higher during acute phase in Group B (69.4% vs. 49.0%, <i>p</i> = 0.04). There was no difference in response during delayed phase in two groups. On univariate analysis, younger patient (<10 years), those with solid tumours, did not receive dexamethasone that had significantly higher odds for breakthrough vomiting in Group A. None of these factors retained significance in multivariate logistic regression analysis. Additional intravenous dose of palonosetron on day 4 is effective in controlling CIV during acute phase in children receiving multiple-day MEC/HEC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"281-289"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taxane-induced macular oedema: disproportionality and timing analyses using FAERS and JADER.","authors":"Naohito Ide, Yoshifumi Kudo, Ken-Ichi Sako, Tomoji Maeda","doi":"10.1080/1120009X.2026.2663679","DOIUrl":"10.1080/1120009X.2026.2663679","url":null,"abstract":"<p><p>Taxanes such as paclitaxel and docetaxel are widely used in malignancies but may cause rare ophthalmic toxicities, including macular oedema. This study clarified occurrence patterns and time to onset by analysing the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER). In total, 4880 macular oedema cases were reported in FAERS and 523 in JADER; 306 and 97 cases were attributed to paclitaxel, and 54 and 13 to docetaxel, respectively. Disproportionality analysis showed positive reporting signals. Median onset times were 115 d in FAERS and 145 d in JADER for paclitaxel and 104 d in FAERS for docetaxel. Weibull shape parameters indicated a random pattern. Outcomes were mostly favourable for paclitaxel, whereas docetaxel cases showed more non-recovery or sequelae in JADER. Taxane-induced macular oedema is a clinically relevant adverse event requiring continuous ophthalmologic monitoring, and potential regional differences and patient-level risk factors warrant further study.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147772733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired <i>CD74-ROS1</i> fusion-mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report.","authors":"Ali Kaan Güren, Erkam Kocaaslan, Yeşim Ağyol, Pınar Erel, Burak Paçacı, Mustafa Alperen Tunç, Ahmet Demirel, Fırat Akagündüz, Abdussamet Çelebi, Selver Işık, Ezgi Çoban, Nazım Can Demircan, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek","doi":"10.1080/1120009X.2026.2657116","DOIUrl":"10.1080/1120009X.2026.2657116","url":null,"abstract":"<p><p>In <i>EGFR</i> T790M-mutant lung adenocarcinoma, the strong and early clinical responses achieved with osimertinib may be limited by the emergence of diverse resistance mechanisms over time. In this case report, we describe an acquired <i>CD74-ROS1</i> fusion that developed during osimertinib therapy in a patient who had an <i>EGFR</i> exon 20 T790M mutation detected in the treatment-naive setting. The fusion, identified through a tissue biopsy performed at the time of progression, suggests that the tumor had activated an alternative oncogenic driver under therapeutic pressure. The combination of osimertinib and crizotinib resulted in a marked clinical and metabolic response, was well tolerated, and the patient remained in remission. This rare case highlights that acquired <i>CD74-ROS1</i> fusions may contribute to osimertinib resistance and suggests that combination targeted therapy may represent a potential therapeutic approach in selected patients.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":2.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of gut microbiome in chemoresistance property development in colorectal cancer tissue and its novel therapeutic strategies.","authors":"Pratikshya Parhi, Amrita Banerjee, Hrudayanath Thatoi","doi":"10.1080/1120009X.2026.2653339","DOIUrl":"10.1080/1120009X.2026.2653339","url":null,"abstract":"<p><p>Colorectal cancer remains the second contributor to cancer-related mortality worldwide. Despite various advances in chemotherapeutic approaches, chemoresistance still poses a significant risk, hampering the effectiveness of the treatment. Recent researches have explored the crucial role of dysbiotic gut microbiota in the progression of CRC. Specific dysbiosed gut microbiota plays a key role in enhancing chemoresistance in CRC patients through different mechanisms by metabolizing drugs, and modulating the immune system, creating a barrier between CRC tissue and chemotherapeutic drugs. Various microbial genes have been linked to chemoresistance that code for different enzymes, resulting in the degradation of chemotherapeutic drugs, thus reducing drug's efficiency and identifying these genes can provide insight into various resistance pathways. Therefore, identifying the microbial signature for predetection of chemoresistance in patient, prevention of colonizing chemoresistance inducing bacteria and interventions like modification of gut flora for enhancing the effectiveness of chemotherapeutics is essential to overcome these challenges.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-28"},"PeriodicalIF":2.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment.","authors":"Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara","doi":"10.1080/1120009X.2025.2479901","DOIUrl":"10.1080/1120009X.2025.2479901","url":null,"abstract":"<p><p>Trifluridine/tipiracil (FTD/TPI) frequently induces chemotherapy-induced nausea and vomiting (CINV). As evidence of factors associated with CINV in oral chemotherapeutic agents is limited, we aimed to assess factors for nausea development in a real-world FTD/TPI-containing treatment for metastatic colorectal cancer (mCRC). Patients with mCRC receiving FTD/TPI with or without bevacizumab (<i>n</i> = 104) were retrospectively evaluated. Nausea occurred in 40.4% of the patients, and the severity was grade 1 for 23.1%, grade 2 for 15.4%, and grade 3 for 1.9%. Multivariable logistic regression analysis suggested that female sex (adjusted odds ratio 2.74, 95% confidence interval 1.02-7.33, <i>p</i> = 0.045) and concomitant bevacizumab (2.68, 1.13-6.37, <i>p</i> = 0.03) were independent risk factors for all-grade nausea during the first cycle as a primary endpoint. Particularly, among patients with FTD/TPI monotherapy, females significantly exhibited nausea compared to males. Our study revealed that concomitant bevacizumab and female sex are independent risk factors for nausea in FTD/TPI-containing treatment for mCRC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"169-176"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy does not decrease 30-day mortality but increases antibiotic consumption in methicillin-sensitive <i>S. aureus</i> bacteraemia.","authors":"Özge Özgen-Top, Pınar Aysert-Yildiz, Hamid Habibi, İbrahim Orhun Hatipoğlu, Elif Ayça Şahin, Zeynep Tekin Taş, Hasan Selçuk Özger, Murat Dizbay","doi":"10.1080/1120009X.2025.2556578","DOIUrl":"10.1080/1120009X.2025.2556578","url":null,"abstract":"<p><strong>Purpose: </strong>The study aimed to compare the impact of combination and monotherapy on mortality, antibiotic consumption using 'Days of Therapy (DOT)', and antibiotic-related adverse events in patients with methicillin-susceptible <i>S. aureus</i> (MSSA) bacteraemia.</p><p><strong>Methods: </strong>This retrospective study included all adult patients (>18 years) with MSSA bacteraemia who received either monotherapy (beta-lactam alone) or combination therapy (beta-lactam plus teicoplanin or daptomycin or linezolid) between 2018 and 2023. Mortality, antibiotic consumption, and factors predicting mortality were analysed. Groups were compared for 30-d mortality with survival analysis. Logistic regression models were used to identify risk factors for mortality. Antibiotic consumption was calculated by DOT.</p><p><strong>Results: </strong>Among 395 patients screened, 185 patients who had an MSSA bacteraemia received either monotherapy (<i>n</i> = 73, 39.5%) or combination therapy (<i>n</i> = 112, 60.5%). The 30-d mortality rate was similar between groups (%15.1 <i>vs.</i> 21.4, <i>P</i> = 0.280). Time to bacterial clearance was also similar (median (IQR): 4 (3-7) <i>vs</i>. 4 (3-7) d, <i>P</i> = 0.699). DOT per 1000 patient days was significantly higher in the combination therapy group than in the monotherapy group (median, IQR: 1420, 827-1836 <i>vs.</i> 933, 732-1000), <i>P</i> < 0.001). The 30-d mortality rate was 18.9% (<i>n</i> = 35/185), and the PITT bacteraemia score was the only independent predictor of mortality (median, IQR: 1506, 1.264-1.794, <i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Our findings indicate that combination therapy does not confer a survival benefit over monotherapy in patients with MSSA bacteraemia. However, combination therapy was associated with a significant increase in antibiotic consumption. Therefore, our results do not support the routine use of combination therapy for MSSA bacteraemia in this patient population.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"138-144"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy extravasation: diagnosis, prevention and management.","authors":"Andrea Duminuco, Giuseppe Novello, Elisa Mauro, Elvira Scalisi, Vittorio Del Fabro, Daniela Sambataro, Giuseppe Palumbo, Francesco Di Raimondo, Demetria Romeo","doi":"10.1080/1120009X.2025.2488599","DOIUrl":"10.1080/1120009X.2025.2488599","url":null,"abstract":"<p><p>Chemotherapy extravasation, the unintended leakage of cytotoxic drugs into surrounding tissues, is a significant complication in oncological treatments, potentially leading to severe tissue damage and long-term consequences. This review explores the factors influencing extravasation risk, including infusion site, patient comorbidities and the physicochemical properties of drugs. Early detection is crucial to prevent irreversible damage. Treatment strategies vary based on the type of drug involved, ranging from topical dimethyl sulfoxide and hyaluronidase to specific antidotes like dexrazoxane for anthracycline extravasations. Preventive measures, including proper catheter placement, drug dilution and patient monitoring, are essential to mitigate risks. Effective management requires a multidisciplinary approach, combining prompt recognition, intervention and ongoing education for healthcare providers to improve patient safety and outcomes in chemotherapy administration. Enhanced training on the early signs of extravasation and advancements in treatment modalities offer critical support in minimizing adverse effects, ensuring timely and appropriate care.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"125-137"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment with oxaliplatin and programmed cell death protein 1 inhibitor in recurrent advanced endometrial carcinoma with mismatch repair defects: a case report and literature review.","authors":"Jian Qiu, Tian Ding, Mingyue Cao, Xiaohong Huang, Yinfeng Wang","doi":"10.1080/1120009X.2025.2466274","DOIUrl":"10.1080/1120009X.2025.2466274","url":null,"abstract":"<p><p>The incidence of endometrial cancer (EC), a widely prevalent gynecological malignancy, is witnessing a global surge. Although early-stage cancer demonstrates promising outcomes, advanced cancer is associated with an unfavorable prognosis. Nevertheless, for specific pathological types or molecular subtypes of advanced EC, an accurate treatment algorithm can lead to a favorable prognosis. Here, we report a case of stage IVB EC characterized by mucinous differentiation with mismatch repair deficiencies (MMRd) who was successfully treated with combination of oxaliplatin and programmed cell death protein 1 (PD-1) inhibitor. Our findings emphasize the importance of conducting pathological and molecular typing assessments in individuals with advanced stage or recurrent EC. Additionally, combining oxaliplatin and PD-1 inhibitors may be a viable treatment option for EC with mucinous differentiation and MMRd. More representative and standardized studies are needed to consolidate this conclusion.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"187-193"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}